Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one allele: 144-week interim results from a 192-week open-label extension study.
Felix C Ringshausen, Yaoyuan Vincent Tan, Valentin Prieto-Centurion, Samuel M Moskowitz, Neil Ahluwalia, Nicholas J Withers, Jennifer L Taylor-Cousar, Hiran Selvadurai, Steven M Rowe, Simon Tian, Bradley S Quon, Deepika Polineni, Edward F McKone, Marcus A Mall, Rachel W Linnemann, Stefano Costa, Elizabeth Tullis, Cori L Daines, Matthias Griese, Bonnie Ramsey, Yaohua Zhang, Fengjuan Xuan, Tanya Weinstock
The European respiratory journal 2024;62(6):2202029